SOURCE: Medpace


December 12, 2013 02:00 ET

MediTech Strategic Consultants B.V. Changes Name to Medpace Medical Device B.V.

CINCINNATI, OH--(Marketwired - Dec 12, 2013) - Medpace Medical Device, a global, full-service medical device contract research organization (CRO) announced that MediTech Strategic Consultants B.V. will now be called Medpace Medical Device B.V., having completed integration activities. Medpace Medical Device B.V., long known throughout the medical device community for its excellent clinical trial conduct and regulatory/quality consultancy in Europe, will continue to be based in Vaals, NL, headquartering the European device operations.

MediTech joined Medpace Medical Device, a fully owned subsidiary of Medpace, Inc. in late 2012 as a strategic European acquisition, expanding Medpace Medical Device capabilities in Europe. This acquisition allowed Medpace to provide regulatory strategy, clinical trial design, and conduct to support medical device companies commercialization efforts in Europe. Over the past year, the two organizations have become fully integrated with regard to all facets of therapeutic and operational excellence-providing unique global solutions for medical device studies.

"The MediTech name change to Medpace Medical Device is the final step in the integration process," said Ryan Wilson, General Manager, Medpace Medical Device. "Our ability to offer robust regulatory consultation, operations, and therapeutic expertise across all stages of device development makes us a premier choice for medical device companies. We can develop and execute a regulatory strategy seamlessly across multiple geographies reducing the time it takes to bring a device to market."

Medpace Medical Device is a full service medical device CRO headquartered in Minneapolis, Minnesota with offices in Dallas, TX, and Vaals, NL. Medpace offers trial design, site management, project management, monitoring, biostatistics, regulatory support, and data management for companies with medical devices in the human clinical trial phase. Medpace Medical Device has the ability to conduct medical device clinical trials for small or large sponsors, and for trials in both the US and worldwide. Medpace Medical Device is a wholly owned subsidiary of Medpace.

Visit Medpace Medical Device at:

Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. 

Medpace creates strategic therapeutic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With 1500+ employees and clinical trial experience in over 45 countries and 6 regions - the US, Europe, Central and Eastern Europe, India, Asia Pacific, and China. Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and central image management and reading from Medpace Imaging Core Lab.

Visit the Medpace website at: